HHS to Add Two Deputy Commissioner Posts at FDA for Tech and Drug Oversight
The Health and Human Services department plans to appoint separate deputy commissioners to steer the FDA's technology integration and drug development efforts.
The U.S. Department of Health and Human Services (HHS) is preparing to expand the Food and Drug Administration’s senior leadership team with two new deputy commissioner positions, one dedicated to technology and the other to drugs. Officials familiar with the plan say the appointments are intended to give the agency a clearer focus on emerging digital health tools, artificial‑intelligence‑driven diagnostics, and the accelerating pace of pharmaceutical innovation.
The technology‑focused deputy commissioner will oversee the FDA’s work on software as a medical device, data‑driven regulatory frameworks, and the agency’s growing portfolio of digital health products. By centralising authority, HHS hopes the FDA can respond more quickly to advances in telemedicine, wearable sensors, and AI algorithms that are increasingly part of patient care.
Meanwhile, the drug‑oriented deputy commissioner will concentrate on streamlining the review and approval process for new medicines, including complex biologics and gene‑therapy products. The role is expected to improve coordination across the agency’s divisions that handle clinical trial oversight, safety monitoring, and post‑market surveillance, addressing concerns that the current system can be fragmented.
Both positions will report directly to the FDA’s commissioner and will require Senate confirmation, with nominations anticipated later in the year. The move follows a series of high‑profile calls from industry groups and lawmakers for the FDA to modernise its regulatory approach as technology and drug development converge.
Analysts view the restructuring as a strategic effort to keep the United States at the forefront of health innovation while maintaining rigorous safety standards. If confirmed, the new deputy commissioners could shape policy on everything from AI‑based diagnostic tools to next‑generation therapeutics, positioning the FDA to better manage the complexities of a rapidly evolving health‑tech landscape.